These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23351021)

  • 1. Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design.
    Douglas RG; Ehlers MR; Sturrock ED
    Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):535-41. PubMed ID: 23351021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme.
    Masuyer G; Douglas RG; Sturrock ED; Acharya KR
    Sci Rep; 2015 Sep; 5():13742. PubMed ID: 26403559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the antifibrotic potential of N-acetyl seryl-aspartyl-lysyl-proline sequence peptides.
    Ramasamy V; Ntsekhe M; Sturrock E
    Clin Exp Pharmacol Physiol; 2021 Nov; 48(11):1558-1565. PubMed ID: 34347311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ac-SDKP, a marker of the angiotensin-converting enzyme activity?].
    Mimouni S; Raffaitin C; Corcuff JB
    Ann Biol Clin (Paris); 2006; 64(1):11-6. PubMed ID: 16420987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis attenuates pulmonary fibrosis in silicotic rats.
    Gao X; Xu H; Zhang B; Tao T; Liu Y; Xu D; Cai W; Wei Z; Li S; Zhang H; Mao N; Zhang G; Li D; Jin F; Li S; Zhang L; Liu H; Hao X; Yang F
    Exp Physiol; 2019 Oct; 104(10):1562-1574. PubMed ID: 31290182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. d-amino acid modification protects N-Acetyl-seryl-aspartyl-lysyl-proline from physiological hydroxylation and increases its antifibrotic effects on hepatic fibrosis.
    Zhang X; Zhou J; Zhu Y; He L; Pang Z; Wang Z; Xu C; Zhang C; Hao Q; Li W; Zhang W; Zhang Y; Li M
    IUBMB Life; 2019 Sep; 71(9):1302-1312. PubMed ID: 30900390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.
    Kumar N; Yin C
    Pharmacol Res; 2018 Aug; 134():268-279. PubMed ID: 29990624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
    Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
    Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.
    Lubbe L; Sewell BT; Sturrock ED
    FEBS J; 2016 Nov; 283(21):3941-3961. PubMed ID: 27636235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain.
    Hrenak J; Paulis L; Simko F
    Curr Pharm Des; 2015; 21(35):5135-43. PubMed ID: 26350537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hemoregulatory peptide N-acetyl-ser-asp-lys-pro impairs angiotensin I-induced contractions in rat aorta.
    Boulanger CM; Ezan E; Massé F; Mathieu E; Lévy BI; Azizi M
    Eur J Pharmacol; 1998 Dec; 363(2-3):153-6. PubMed ID: 9881583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New ketomethylene inhibitor analogues: synthesis and assessment of structural determinants for N-domain selective inhibition of angiotensin-converting enzyme.
    Sharma RK; Douglas RG; Louw S; Chibale K; Sturrock ED
    Biol Chem; 2012 May; 393(6):485-93. PubMed ID: 22628311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis.
    Junot C; Gonzales MF; Ezan E; Cotton J; Vazeux G; Michaud A; Azizi M; Vassiliou S; Yiotakis A; Corvol P; Dive V
    J Pharmacol Exp Ther; 2001 May; 297(2):606-11. PubMed ID: 11303049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides.
    Masuyer G; Schwager SL; Sturrock ED; Isaac RE; Acharya KR
    Sci Rep; 2012; 2():717. PubMed ID: 23056909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.
    Rhaleb NE; Peng H; Harding P; Tayeh M; LaPointe MC; Carretero OA
    Hypertension; 2001 Mar; 37(3):827-32. PubMed ID: 11244003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
    Azizi M; Rousseau A; Ezan E; Guyene TT; Michelet S; Grognet JM; Lenfant M; Corvol P; Ménard J
    J Clin Invest; 1996 Feb; 97(3):839-44. PubMed ID: 8609242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Acetyl-Seryl-Asparyl-Lysyl-Proline regulates lung renin angiotensin system to inhibit epithelial-mesenchymal transition in silicotic mice.
    Li S; Li Y; Zhang Y; Li S; Zhang M; Jin F; Wei Z; Yang Y; Gao X; Mao N; Ge X; Xu H; Yang F
    Toxicol Appl Pharmacol; 2020 Dec; 408():115255. PubMed ID: 33007385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Angiotensin converting enzyme domain structure and properties].
    Kugaevskaia EV
    Biomed Khim; 2005; 51(6):567-80. PubMed ID: 16521820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats.
    Sharp S; Poglitsch M; Zilla P; Davies NH; Sturrock ED
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1149-58. PubMed ID: 25757657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors.
    Douglas RG; Sharma RK; Masuyer G; Lubbe L; Zamora I; Acharya KR; Chibale K; Sturrock ED
    Clin Sci (Lond); 2014 Feb; 126(4):305-13. PubMed ID: 24015848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.